LOXL2 and pulmonary fibrosis: Studies in a bleomycin-induced pulmonary fibrosis model strongly suggested that LOXL2 was an attractive target in fibrosis [16] and lead to a clinical trial designed to investigate the efficacy and safety of Simtuzumab, a monoclonal antibody against LOXL2, in patients with IPF [18].